

U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: OC01620K APPLICANT: APPLICATION NO.: 10/654,163

INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT: Tim thy J. Guzi tal.						
(Use several sheets if necessary)					FILING DATE: 09/03/2003			GROUP 624			
U.S. PATENT DOCUMENTS											
'EXAMINER DOCUMENT				DATE	NAME		CL	ASS	SUB- CLASS	FILING	
INITI	AL	44	NUMBER	11/05/1996	Rühter et al.		-	1	CLASS	APPRO	PRIATE
├		AA AB	US 5,571,813 US 5,602,136	02/11/1997	Rühter et al.			+-	 	 	
 	1-	AC	US 5,602,137	02/11/1997	Rühter et al.			 	 		
	+	AD	US 5,688,949	11/18/1997	Inoue et al.		_	1	 		$\neg \neg$
	+-	ΑE	US 5,707,997	01/13/1998	Shoji et al.			1			
-	+	AF	US 5,919,815	07/06/1999	Bradley et al.			-	 		
	1	AG	US 6,040,321	03/21/2000	Kim et al.						
—	1	AH	US 6,191,131	02/20/2001	He et al.					<u> </u>	
<u> </u>	17	AJ	US 6,262,096	07/17/2001	Kim et al.		\Box		7		
		AJ	US 6,413,974	07/02/2002	Dumont et al.		Π		II		
FOREIGN PATENT DOCUMENTS											
			DOCUMENT	DATE	COUNTRY		CLASS	ASS	SUB-	TRANS	LATION
<u> </u>	ŀ		NUMBER				1		CLASS	YES	NO
7	/	AK	EP 0 628 559	04/03/2002	Eur	оре					
		AL	EP 1 334 973	08/13/2003	Eur	оре					
		AM	WO 02/40485	05/23/2002	. P(CT					
		ÁN	WO 02/50079	06/27/2002		CT	<u> </u>			.	
	AO WO 95/3		WO 95/35298	12/28/1995	PCT .		<u>L_</u>		<u> </u>	<u></u>	
		OTI	HER DOCUMENT	TS (Including	Author, Title	e, Date, Pert	iner	nt Pa	iges, Et	c.)	
0	11	AP	Vesely et al., "Inhibi		ependent Kina	ses by Purine A	malo	gues	", Eur. J.	Bloche	m
	5		(1994), 224: 771-78	6							
1		AQ	Kim et al., "Discove	ry of Aminothia	zole inhibitors o	of Cyclin-Depen	iden	t Kina	ase 2: Syl	ntnesis,	x-ray
			Crystallographic Analysis, and Biological Activities", Journal of Medical Chemistry, Page								
<u> </u>	╂	45	EST:22.3, A-W.								
	AR Mettey et al., "Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structur in								1. 222-		
1.		,	Complex with CDK2, Enzyme Selectivity, and Cellular Effects", J. Med. Chem. (2003), 46(2): 222-								
	1-	AS	236. Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-								
	1 1	~	a]pyrimidines", J. Med. Chem. (1977), 20(2): 296-299.								
		AT	T Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent								
	Kinase Inhibitor, in Patients with Refractory Neoplasms", Journal of Clinical Oncology (September										
	1998), 16(9): 2986-2999.										
AU Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibito											
the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", Eur. J. Biochem. (1997), 243:527-							-330.				
AV Bible et al., "Cytotoxic Synergy Between Flavopindol (NSC 64989							iU, L	00-02	erojana. Poda Pod	various,	MA. Δuguet
Antineoplastic Agents: The Importance of Sequence of Administration", Cancer Research (Aug								August			
	٠ .	1000	15, 1997), 57: 3375-3380. N Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin								
		ΙΔΙΛΙ	Il Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine Derivatives", Chem. Pharm. Bull. (1999), 47(7):								
l i		AW	Il Recentor Antagor	ists: Pyrazoloľ	1.5-alovrimidine	e Derivatives". (Cher	n. Ph	arm. Bull	(1999)	. 47(7):
		AW	II Receptor Antagor	nists: Pyrazolo[1,5-α]pyrimidine	e Derivatives", (Cher	n. Ph	arm. Bull	. (1999)	, 47(7):
N		AX	II Receptor Antagor 928-938.	nists: Pyrazolo[arm. Bull	. (1999)	
O			II Receptor Antagor	hists: Pyrazolo[Studies on the	Azaindolizine Co n. Pharm. Bull (ompounds. XI. 1962), 10: 620-	Synt	hesis	arm. Bull	. (1999)	
EXAM	HINEF	AX	II Receptor Antagor 928-938. Yasuo Makisumi, "S	hists: Pyrazolo[Studies on the	Azaindolizine Co n. Pharm. Bull (ompounds. XI.	Synt	hesis	arm. Bull	. (1999)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAR 2 2 2004

DUPLICATE

Sheet 1 of 1

		4 4 4 6		0.4071461-		T-,					
DRA	FORD PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY, DOCKE OC01620K	APPLICATION NO.: 10/654,163					
	INFORMATION DISCLOSURE STATEMENT								APPLICANT:		
							Timothy J. Guzi et al.				
						FILING DATE:	GROUP:				
		(Use several sheets if necessar				y) 09/03/2003			G11007 .		
	U.S. PATENT DOCUMENTS										
	*EXAMINER		DOCUMENT	DATE	NAI	ME	CLASS	SUB-	FILING DATE IF		
	INITIAL	<u> </u>	NUMBER	<u> </u>			<u> </u>	CLASS	APPROPRIATE		
		AA		ļ	ļ		↓	ļ			
		AB					<u> </u>	<u> </u>	ļ		
		AC AD	 -	 	 		 		ļ		
1	·	AE		 	 		 	<u> </u>			
		AF		 	 		 	 			
		AG	•	 			 	<u> </u>	 -		
		AH		 	 		 		 		
		Al		 	 		 		 		
		AJ					 			——	
		AK		<u> </u>	· · · · · · · · · · · · · · · · · · ·		· · · · · · · ·				
				OREIGN	PATENT DOC	UMENTS	<u>. </u>				
			DOCUMENT	COUNTRY	OMENTO	CLASS	SUB- TRANSLATION				
			NUMBER	DATE			100.00	CLASS	YES	NO	
	1/4/	AL	DE 102 23 917 A1	12/11/2003	Germ	anv		00.00			
1		AM	EP 1 199 306 A1	04/24/2002	Euro						
		AN		06/05/1996	Europe						
,	1/	AO	WO 02/50079 A1	06/27/2002	WIPO				•		
٠	<u>u</u>	AP	WP 03/091256 A1	11/06/2003	WIPO						
.		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
- 1	Λ	AQ Adrian M. Senderowicz et al., "Preclinical and Clinical Development of Cyclin-Dependent Kinase									
	Modulators", J. Natl. Cancer Inst., 92(5):376-387 (March 1, 2000).										
	11	AR	Teruki Honma et al., "Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New								
de Novo Design Strategy and Library Design", J. Med. Chem., 44: 4615-4627 (2 AS Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Pro								27 (2001)		
ŀ		AS	Translation of WO 0	<u>3/91256, A Ri</u>	sing Sun Commu	inications Ltd.	Translatio	n Produc	1, (1-62)		
ŀ		AT									
ł		AU AV									
ŀ	EXAMINER		1/1	-/	DATE CO	NSIDERED					
	Ç I		. 1/ 1	// _	DATECC	INSIDERED.				l	
1		}	12 1UC	19		6/11	In				
1	*EXAMINE	1: In	itial if reference consi	dered, whether	er or not citation i	s in conforman	with M	PEP 609	Draw I	ine	
I through citation if not in conformance and net considered. Include copy of this form with							with next	commur	ication t	0	
L	applicant.							~		- 1	